First published in the Government *Gazette*, Electronic Edition, on 30 April 2020 at 5 pm.

No. S 350

MISUSE OF DRUGS ACT
(CHAPTER 185)

MISUSE OF DRUGS (AMENDMENT)
REGULATIONS 2020

In exercise of the powers conferred by section 58(1) of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Regulations:

Citation and commencement

1. These Regulations are the Misuse of Drugs (Amendment) Regulations 2020 and come into operation on 1 May 2020.

Amendment of Second Schedule

2. Paragraph 10 of the Second Schedule to the Misuse of Drugs Regulations (Rg 1) is amended —

(*a*) by inserting, immediately after item (9), the following item:

"(9AAA) Crotonylfentanyl"; and

(*b*) by inserting, immediately after item (15), the following item:

"(16) Valerylfentanyl".

Amendment of Fourth Schedule

3. The Fourth Schedule to the Misuse of Drugs Regulations is amended —

(*a*) by deleting item (2) of paragraph 1 and substituting the following item:

"(2) 1-(4-Bromo-2,5-dimethoxyphenyl)propan-2-amine (also known as 4-Bromo-2,5-dimethoxy-α-methylphenethylamine,

4-Bromo-2,5-dimethoxyamphetamine, Brolamfetamine or DOB) and its bromo and dimethoxy positional isomers in the phenyl ring";

(*b*) by deleting item (12) of paragraph 1 and substituting the following item:

"(12) 1-(2,5-Dimethoxy-4-methylphenyl)propan-2-amine (also known as 2,5-Dimethoxy-4, α-dimethylphenethylamine, 2-Amino-1-(2,5-dimethoxy-4-methyl)phenylpropane or DOM) and its methyl and dimethoxy positional isomers in the phenyl ring";

(*c*) by deleting item (12A) of paragraph 15 and substituting the following item:

"(12A) 2-(Ethylamino)-1-phenylhexan-1-one (also known as N-Ethylhexedrone or Ethyl-hexedrone)";

(*d*) by inserting, immediately after item (24) of paragraph 15, the following item:

"(24A) 1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one (also known as Alpha-Pyrrolidinohexiophenone or Alpha-PHP or α-PHP)";

(*e*) by inserting, immediately after item (2) of paragraph 17, the following item:

"(2AAA) 6-Allyl-6-nor-lysergic acid diethylamide (also known as N-Allyl-nor-LSD or AL-LAD) and its acyclic secondary and tertiary amide structural isomers";

(*f*) by inserting, immediately after item (2A) of paragraph 17, the following item:

"(2AAB) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide (also known as 2-[(1-Butyl-1H-indazol-3-yl)formamido]-3,3-dimethylbutanamide or ADB-BUTINACA) and its N-(1-amino-1-oxohexan-2-yl) isomers";

(*g*) by inserting, immediately after item (2CA) of paragraph 17, the following item:

"(2CB) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-hydroxybutyl)-1H-indazole-3-carboxamide and its

N-(1-amino-1-oxohexan-2-yl) isomers and their respective hydroxy positional isomers in the butyl group";

(*h*) by deleting item (2G) of paragraph 17 and substituting the following item:

"(2G) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as N-[1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide or AB-FUBINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers and their respective fluoro positional isomers in the phenyl ring";

(*i*) by inserting, immediately after item (6G) of paragraph 17, the following items:

"(6H) 1-Butanoyl-N,N-diethyllysergamide (also known as 1-Butanoyl-LSD or 1B-LSD) and its acyclic secondary and tertiary amide structural isomers

(6I) 2-(1-Butyl-1H-indazole-3-carboxamido)-3,3-dimethylbutanoic acid and its hexanoic acid isomers";

(*j*) by inserting, immediately after item (8A) of paragraph 17, the following item:

"(8AAA) 1-(4-Chloro-2,5-dimethoxyphenyl)propan-2-amine (also known as 4-Chloro-2,5-dimethoxy-α-methylphenethylamine, 4-Chloro-2,5-dimethoxyamphetamine, DOC, 3C-C, 4-Cl-2,5-DMA or 4-Chloro-2,5-DMA) and its chloro and dimethoxy positional isomers in the phenyl ring";

(*k*) by inserting, immediately after item (14) of paragraph 17, the following item:

"(14A) 2-[1-(4,5-Dihydroxypentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid and its hexanoic acid isomers and their respective dihydroxy positional isomers in the pentyl group";

(*l*) by inserting, immediately after item (19AAB) of paragraph 17, the following item: